Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: Why the 4:1 ratio for treatment?

Drug and Alcohol Dependence

Volumn 70, Issue 2 SUPPL., 2003, Pages

  Mendelson, John ^a   Jones, Reese T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Buprenorphine; Dependence; Naloxone; Opiate; Treatment

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; HYDROMORPHONE; METHADONE; MORPHINE; MU OPIATE RECEPTOR AGONIST; NALOXONE; NALTREXONE;

ANALGESIA; ATTENUATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG DEPENDENCE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MISUSE; DRUG TOLERABILITY; DRUG TRAFFIC; HEROIN DEPENDENCE; HUMAN; OPIATE ADDICTION; POSTOPERATIVE PAIN; PRIORITY JOURNAL; REVIEW; SUBSTITUTION THERAPY; WITHDRAWAL SYNDROME;

EID: 0037987960     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(03)00057-7     Document Type: Review

References (54)

1. Comer S.D., Collins E.D. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. J. Pharmacol. Exp. Ther. 303:2002;695-703.
2. Cracowski J.L., Mallaret M., Vanzetto G. Myocardial infarction associated with buprenorphine (Ltr). Ann. Inter. Med. 130:1999;536. discussion 536-537.
3. Eder H., Fischer G., Gombas W., Jagsch R., Stuhlinger G., Kasper S. Comparison of buprenorphine and methadone maintenance in opiate addicts. Eur. Addict. Res. 4:(Suppl. 1):1998;3-7.
4. Eissenberg T., Greenward M.K., Johnson R.E., Liebson I.A., Bigelow G.E., Stitzer M.L. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans. J. Pharmacol. Exp. Ther. 276:1996;449-459.
5. Eissenberg T., Johnson R.E., Bigelow G.E., Walsh S.L., Liebson I.A., Strain E.C., Stitzer M.L. Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. Drug Alcohol Depend. 45:1997;81-91.
6. Fischer G., Johnson R.E., Eder H., Jagsch R., Peternell A., Weninger M., Langer M., Aschauer H.N. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction. 95:2000;239-244.
7. Fraser H.F., Isbell H. Human pharmacology and addiction liabilities of phenazocine and levophenacylmorphan. Bull. Narcot. 12:1960;15-23.
8. Fudala P.J., Yu E., Macfadden W., Boardman C., Chiang C.N. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend. 50:1998;1-8.
9. Ghodse A.H. Analysis of epidemiological data on agonist-antagonist analgesics. Drug Alcohol Depend. 20:1987;375-383.
10. Gilman A.G., Rall T.W., Nies A.S., Taylor P. Goodman and Gilman's The Pharmacological Basis of Therapeutics. eighth ed. 1990;Pergamon Press, New York.
11. Harris D.S., Jones R.T., Welm S., Upton R.A., Lin E., Mendelson J. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend. 61:2000;85-94.
12. Jasinski D.R. Assessment of the abuse potentiality of morphine-like drugs (Methods used in man). Martin W.R. Drug Addiction I. Berlin. 1977;Springer, Berlin.
13. Jasinski D.R. Human pharmacology of narcotic antagonists. Br. J. Clin. Pharmacol. 7:(Suppl. 3):1979;287S-290S.
14. Jasinski D.R., Fudala P.J., Johnson R.E. Sublingual versus subcutaneous buprenorphine in opiate abusers. Clin. Pharmacol. Ther. 45:1989;513-519.
15. Jasinski D.R., Pevnick J.S., Griffith J.D. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch. Gen. Psychiatry. 35:1978;501-516.
16. Johnson R.E., Eissenberg T., Stitzer M.L., Strain E.C., Liebson I.A., Bigelow G.E. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend. 40:1995;17-25.
17. Johnson R.E., Jaffe J.H., Fudala P.J. A controlled trial of buprenorphine treatment for opioid addiction. J. Am. Med. Assn. 267:1992;2750-2755.
18. Johnson R.E., Jones H.E., Jasinski D.R., Svikis D.S., Haug N.A., Jansson L.M., Kissin W.B., Alpan G., Lantz M.E., Cone E.J., Wilkins D.G., Golden A.S., Huggins G.R., Lester B.M. Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend. 63:2001;97-103.
19. Kanof P.D., Aronson M.J., Ness R., Cochrane K.J., Horvath T.B., Handelsman L. Levels of opioid physical dependence in heroin addicts. Drug Alcohol Depend. 27:1991;253-262.
20. Kosten T.R., Krystal J.H., Charney D.S., Price L.H., Morgan C.H., Kleber H.D. Opioid antagonist challenges in buprenorphine maintained patients. Drug Alcohol Depend. 25:1990;73-78.
21. Lavelle T.L., Hammersley R., Forsyth A. The use of buprenorphine and temazepam by drug injectors. J. Addict. Dis. 10:1991;5-14.
22. Ling W., Charuvastra C., Collins J.F., Batki S., Brown L.S. Jr., Kintaudi P., Wesson D.R., McNicholas L., Tusel D.J., Malkerneker U., Renner J.A. Jr., Santos E., Casadonte P., Fye C., Stine S., Wang R.I., Segal D. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 93:1998;475-486.
23. Ling W., Wesson D.R., Charuvastra C., Klett C.J. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch. Gen. Psychiatry. 53:1996;401-407.
24. Loimer N., Presslich O., Grunberger J., Linzmayer L. Combined naloxone/methadone preparations for opiate substitution therapy. J. Subst. Abuse Treat. 8:1991;157-160.
25. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., Gilbert P.E. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197:1976;517-532.
26. Mendelson J., Jones R.T., Fernandez I., Welm S., Melby A.K., Baggott M.J. Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clin. Pharmacol. Ther. 60:1996;105-114.
27. Mendelson J., Jones R.T., Welm S., Baggott M., Fernandez I., Melby A.K., Nath R.P. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology. 141:1999;37-46.
28. Mendelson J., Jones R.T., Welm S., Brown J., Batki S.L. Buprenorphine and naloxone interactions in methadone maintenance patients. Biol. Psychiatry. 41:1997;1095-1101.
29. Mendelson J., Upton R.A., Everhart E.T., Jacob P. III, Jones R.T. Bioavailability of sublingual buprenorphine. J. Clin. Pharmacol. 37:1997;31-37.
30. Mendelson J.H., Mello N.K., Teoh S.K., Lloyd-Jones J.G., Clifford J.M. Naloxone suppresses buprenorphine stimulation of plasma prolactin. J. Clin. Psychopharmacol. 9:1989;105-109.
31. Nigam A.K., Srivastava R.P., Saxena S., Chavan B.S., Sundaram K.R. Naloxone-induced withdrawal in patients with buprenorphine dependence. Addiction. 89:1994;317-320.
32. Nutt J.G., Jasinski D.R. Methadone-naloxone mixtures for use in methadone maintenance programs. Clin. Pharmacol. Ther. 15:1974;156-166.
33. O'Brien C.P., Greenstein R., Ternes J., Woody G.E. Clinical pharmacology of narcotic antagonists. Ann. NY Acad. Sci. 311:1978;232-239.
34. O'Connor J.J., Moloney E., Travers R., Campbell A. Buprenorphine abuse among opiate addicts. Br. J. Addict. 83:1988;1085-1087.
35. Olley J.E., Tiong G.K. Plasma levels of opioid material in man following sublingual and intravenous administration of buprenorphine: exogenous/endogenous opioid interaction? J. Pharm. Pharmacol. 40:1988;666-667. letter.
36. Preston K.L., Bigelow G.E., Liebson I.A. Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology (Berl.). 94:1988;484-490.
37. Preston K.L., Bigelow G.E., Liebson I.A. Effects of sublingually given naloxone in opioid-dependent human volunteers. Drug Alcohol Depend. 25:1990;27-34.
38. Robinson G.M., Dukes P.D., Robinson B.J., Cooke R.R., Mahoney G.N. The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand. Drug Alcohol Depend. 33:1993;81-86.
39. Rolly G., Poelaert J., Mungroop H., Paelinck H. A combination of buprenorphine and naloxone compared with buprenorphine administered intramuscularly in postoperative patients. J. Int. Med. Res. 14:1986;148-152.
40. San L., Torrens M., Castillo C., Porta M., de la Torre R. Consumption of buprenorphine and other drugs among heroin addicts under ambulatory treatment: results from cross-sectional studies in 1988 and 1990. Addiction. 88:1993;1341-1349.
41. Schottenfeld R.S., Pakes J.R., Oliveto A., Ziedonis D., Kosten T.R. Buprenorphine versus methadone maintenance for concurrent opioid dependence and cocaine abuse. Arch. Gen. Psychiatry. 54:1997;713-720. see comments.
42. Schuh K.J., Walsh S.L., Bigelow G.E., Preston K.L., Stitzer M.L. Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans. J. Pharmacol. Exp. Ther. 278:1996;836-846.
43. Segui J., Cascio A., Aragon C., Llovet J.M., Soler J.M., Salvador L. The prevalence of buprenorphine consumption in a sample of outpatient drug abusers. Rev. Clin. Esp. 189:1991;14-17.
44. Singh R.A., Mattoo S.K., Malhotra A., Varma V.K. Cases of buprenorphine abuse in India. Acta Psychiatry Scand. 86:1992;46-48.
45. Stoller K.B., Bigelow G.E., Walsh S.L., Strain E.C. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl.). 154:2001;230-242.
46. Strain E.C., Preston K.L., Liebson I.A., Bigelow G.E. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J. Pharmacol. Exp. Ther. 261:1992;985-993.
47. Strain E.C., Preston K.L., Liebson I.A., Bigelow G.E. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. J. Pharmacol. Exp. Ther. 272:1995;628-638.
48. Strain E.C., Stitzer M.L., Liebson I.A., Bigelow G.E. Buprenorphine versus methadone in the treatment of opioid-dependence: self-reports, urinalysis, and addiction severity index. J. Clin. Psychopharmacol. 16:1996;59-67.
49. Strain E.C., Stoller K., Walsh S.L., Bigelow G.E. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology (Berl.). 148:2000;374-383.
50. Vanacker B., Vandermeersch E., Tomassen J. Comparison of intramuscular buprenorphine and a buprenorphine/naloxone combination in the treatment of post-operative pain. Curr. Med. Res. Opin. 10:1986;139-144.
51. Walsh S.L., June H.L., Schuh K.J., Preston K.L., Bigelow G.E., Stitzer M.L. Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology (Berl.). 119:1995;268-276.
52. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., Bigelow G.E. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin. Pharmacol. Ther. 55:1994;569-580.
53. Weinberg D.S., Inturrisi C.E., Reidenberg B., Moulin D.E., Nip T.J., Wallenstein S., Houde R.W., Foley K.M. Sublingual absorption of selected opioid analgesics. Clin. Pharmacol. Ther. 44:1988;335-342.
54. Weinhold L.L., Preston K.L., Farre M., Liebson I.A., Bigelow G.E. Buprenorphine alone and in combination with naloxone in nondependent humans. Drug Alcohol Depend. 30:1992;263-274.